Section Arrow
ELVN.NASDAQ
- Enliven Therapeutics
Quotes are at least 15-min delayed:2025/11/16 04:41 EST
Regular Hours
Last
 22.07
+1.8 (+8.88%)
Day High 
22.32 
Prev. Close
20.27 
1-M High
24.64 
Volume 
565.73K 
Bid
16.66
Ask
22.19
Day Low
19.84 
Open
19.88 
1-M Low
16.8 
Market Cap 
1.20B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 19.58 
20-SMA 20.59 
50-SMA 20.19 
52-W High 26.48 
52-W Low 13.3 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.99/-2.19
Enterprise Value
1.20B
Balance Sheet
Book Value Per Share
8.02
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 04:41 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.